Turkmenistan Registration Timeline: The 180-Calendar-Day Statutory Limit

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The statutory deadline for national registration in Turkmenistan is: no more than 180 calendar days from the moment of acceptance of the application.

The key lies in what these 180 days exclude. The regime statements expressly exclude three segments of time:

  1. The time needed by the applicant to pay the state fees;
  2. The duration of laboratory analysis;
  3. The time taken to respond to queries (questions and comments).

In other words, the 180 days are net review time, not a project timeline. Applicants should therefore read the statutory deadline as the review window only, and plan payment, testing, legalization and query responses around it as separate schedule items.

2. Legal basis

Legal instrumentReference / numberPublication dateProvisions
Law of Turkmenistan on Drug ProvisionNo. 319-VJanuary 12, 2016Timeline of the national registration procedure (no more than 180 calendar days)
Regulation on the State Registration of Medicines and Medical DevicesNo public number (approved by the Ministry of Health)Current versionAcceptance, review, laboratory analysis and issuance procedure

3. Expert insights

Insight 1: the 180 days are counted in calendar days, not working days — a strict formulation.

180 calendar days correspond roughly to 6 months; if the same number of days were counted as working days, the span would be about 8.5 calendar months. Using calendar days means the official constraint on the authority itself is tighter, but it also means companies must not treat the figure as a rounded 6 months when building buffers into their schedules. For budgeting purposes, the difference between a calendar-day reading and a working-day reading is roughly ten weeks, which is material for tender deadlines.

Insight 2: the three excluded segments are precisely the variables the applicant controls most.

Payment of fees, laboratory analysis and responses to queries — of these three, fee payment and responses to queries are entirely in the hands of the applicant. The practical implication is clear: the largest source of project delay is not slow review but slow responses to deficiency requests. Applicants who respond to queries within days rather than months routinely finish much closer to the statutory limit. Article 48 of this series describes the main types of deficiency requests.

Insight 3: the starting point is the acceptance of the application, not the submission of the dossier.

The statutory wording is from the moment of the Application reception. Between submission and acceptance there is a formal completeness check. If the dossier is incomplete, acceptance does not occur and the 180-day clock never starts. The acceptance stage typically verifies the formal completeness of the file: signatures, legal status documents, translations and payment references. This is a typical design in which dossier completeness determines the starting point.

Insight 4: the industry-reported timelines are far longer than 180 days, and the two do not contradict each other.

Different sources report actual timelines of 5–6 months, 6–12 months and 12–18 months — a wide spread. They do not contradict the 180 days: they include fee payment, laboratory analysis, responses to queries and the applicant’s own preparation time. The spread across sources also reflects differences in product type, local testing needs and the responsiveness of each applicant. Our handling is to present the statutory figure and the industry figures side by side and explain the difference in scope.

Insight 5: the figure is a ceiling, not an average.

The statutory wording is must not exceed 180 calendar days. It is a ceiling, which means that in theory the process can be faster and the authority is obliged to complete it within this period. If the deadline is exceeded, the applicant may assert procedural rights on this basis — but the assertion must be made in writing through the local representative. In practice, written reminders submitted through the local representative are the standard instrument for invoking this obligation.

4. Practical recommendations

  1. Model the project schedule as 180 days plus the three excluded segments; never substitute 180 days for the total timeline.
  2. Set internal deadlines for fee payment and responses to queries, compressing both segments to the minimum.
  3. Run a full formal completeness check before submission, to secure acceptance at the first attempt and start the clock as early as possible.
  4. Estimate laboratory analysis time in advance, especially for products requiring local testing, and reflect the estimate in the project plan as a separate block.
  5. Give external stakeholders both the statutory figure and the actual timeline range, to avoid distorted commitments.

5. Verification checklist

  • □ The schedule model contains all four segments: 180 days + fee payment + laboratory analysis + responses to queries.
  • □ Internal deadlines are set for fee payment and responses to queries.
  • □ A formal completeness check has been completed before submission.
  • □ Laboratory analysis time has been estimated in advance.
  • □ External documents present both the statutory figure and the actual range.

Regulatory information verified as of October 30, 2026. The content cited in this document was checked against the provisions of Law No. 319-V on Drug Provision (January 12, 2016) on the 180-calendar-day limit of the national registration procedure and its exclusions; the industry-reported ranges of 5–6 months, 6–12 months and 12–18 months are actual timelines including preparation and deficiency responses, are practical estimates, and are not of the same scope as the statutory 180 days.

GRZAN support in Turkmenistan: GRZAN provides registration support to manufacturers, importers and authorized representatives for this market. Local resources can be coordinated, including licensed importing entities and authorized representative arrangements, covering national registration submission, the consular legalization chain for documents, delivery of samples, alignment with mandatory TDS certification, and customs clearance support. Service capabilities include classification judgment, selection of the registration pathway, preparation of dossiers in the national format, notarization and consular legalization, preparation of testing and stability documentation, organization of GMP and ISO 13485 evidence, variations and renewal, and vigilance and post-market maintenance. Contact: info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail